Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mahendra D. Chordia has a total of 334 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Click-based determination of accumulation of molecules in Escherichia coli

    by George M. Ongwae, Zichen Liu, Shasha Feng, Mahendra D. Chordia, Rachita Dash, Yuchen He, Mohammad Sharifian Gh, Brianna E. Dalesandro, Taijie Guo, Karl Barry Sharpless, et al.

    Gram-negative bacterial pathogens pose a significant challenge in drug development because their outer membranes hinder the permeation of small molecules. The lack of widely adoptable methods for measuring the cytosolic accumulation of compounds in bacterial cells further hinders drug discovery efforts. To address this challenge, we report the development of the Chloroalkane Azide Membrane Permeability (CHAMP) assay, which we designed specifically to assess molecule accumulation in the cytosol of Gram-negative bacteria. The CHAMP analysis utilizes bioorthogonal epitopes anchored within HaloTag-expressing bacteria and measures the cytosolic arrival of azide-bearing test molecules through strain-promoted azide–alkyne cycloaddition. This workflow enables robust and rapid accumulation measurements of thousands of azide-tagged small molecules. Our approach consistently produces comprehensive accumulation profiles that surpass the scale of previous measurements in Escherichia coli ( E. coli ). We validated the CHAMP assay across various chemical and biological contexts, including hyperporinated cells, membrane-permeabilized cells, and E. coli strains with impaired TolC function, a key component of the efflux pump. The CHAMP platform provides a simple, high-throughput, and accessible method that enables the analysis of over 1000 molecules within hours. This technique addresses a critical gap in antimicrobial research and has the potential to accelerate the development of effective agents against Gram-negative pathogens.


  • The Mycomembrane Differentially and Heterogeneously Restricts Antibiotic Permeation

    by Irene Lepori, Kiserian Jackson, Zichen Liu, Mahendra D. Chordia, Mitchell Wong, Sylvia L. Rivera, Marta Roncetti, Laura Poliseno, Joel S. Freundlich, Marcos M. Pires, et al.

    The recalcitrance of Mycobacterium tuberculosis to antibiotic treatment has been broadly attributed to the impermeability of the organism's outer mycomembrane. However, the studies that support this inference have been indirect or reliant on bulk population measurements. We previously developed the Peptidoglycan Accessibility Click-Mediated AssessmeNt (PAC-MAN) method to covalently trap azide-modified small molecules in the peptidoglycan cell wall of live mycobacteria after they have traversed the mycomembrane. Using PAC-MAN, we now show that the mycomembrane differentially restricts access to fluorophores and antibiotic derivatives. Mycomembranes of both M. tuberculosis and the model organism Mycobacterium smegmatis discriminate between divergent classes of antibiotics as well as between antibiotics within a single family, the fluoroquinolones. By analyzing subpopulations of M. tuberculosis and M. smegmatis, we also found that some fluorophores and vancomycin are heterogeneously restricted by the mycomembrane. Our data indicate that the mycomembrane is a molecule- and cell-specific barrier to antibiotic permeation.


  • Enhanced prediction of antigen and antibody binding interface using ESM-2 and Bi-LSTM

    by Qianying Li, Yanmin Zhao, Mahendra D. Chordia, Xiuming Xia, Bo Zhang, Heping Zheng


  • Effect of Atomic Size and Stereochemistry of Halogenated Hydantoin Derivatives on Main Protease Inhibition Activities of SARS-CoV-2: Rationalization Through Computational Studies

    by Anushri Pal, Mahendra D. Chordia

    A recent report discovered a chloro-hydantoin lead for COVID-19 antiviral therapy, however, effects of stereochemical changes of the spiro-cycle and halogens were not examined. Herein, we describe how minimal structural variations, such as stereochemistry and atomic size of halogen substituents, affect binding affinity and biological activity. Blind docking derived a correlation between binding affinity and IC 50 of various hydantoin analogs revealed the F compound 8 (2s, 4s) to be more potent than Cl compound 9a (2s, 4s) and Br compound 10a (2s, 4s). However, experimentally, Cl compound 9a and Br compound 10a exhibited greater in vitro potency against M pro than F compound 8. To rationalize the impact of atomic size and stereo configuration on observed biological activity, the volume occupancy and protein-ligand interactions were evaluated. Compounds 9a and 10a occupy 33% and 35% of the cavity space. The Br atom's size optimally fits the cavity with less conformational flexibility, conferring higher stability. MD simulation data of the ligand torsion profile and the solvent accessible surface area also indicated higher conformational stability for compound 10a than compounds 8 and 9a. Compounds 9b and 10b, (2r, 4r) stereoisomers of 9a and 10a respectively, had more conformational flexibility and were less active M pro inhibitors in vitro.


  • Open Access

    Effect of atomic size and stereochemistry of halogenated hydantoin derivatives on main protease inhibition activities of SARS-CoV-2: Rationalization through computational studies

    by Anushri Pal, Mahendra D Chordia

    A recent report discovered a chloro-hydantoin lead for COVID-19 antiviral therapy, however, effects of stereochemical changes of the spiro-cycle and halogens were not examined. Herein, we describe how minimal structural variations, such as stereochemistry and atomic size of halogen substituents, affect binding affinity and biological activity. Blind docking derived a correlation between binding affinity and IC50 of various hydantoin analogs revealed the F compound 8 (2s, 4s) to be more potent than Cl compound 9a (2s, 4s) and Br compound 10a (2s, 4s). However, experimentally, Cl compound 9a and Br compound 10a exhibited greater in vitro potency against Mpro than F compound 8. To rationalize the impact of atomic size and stereo configuration on observed biological activity, the volume occupancy and protein-ligand interactions were evaluated. Compounds 9a and 10a occupy 33% and 35% of the cavity space. The Br atom’s size optimally fits the cavity with less conformational flexibility, conferring higher stability. MD simulation data of the ligand torsion profile and the solvent accessible surface area also indicated higher conformational stability for compound 10a than compounds 8 and 9a. Compounds 9b and 10b, (2r, 4r) stereoisomers of 9a and 10a, had more conformational flexibility and were less active Mpro inhibitors in vitro.

  • Targeted Antioxidant Therapy Reduces Hyperglycemic Exacerbation of Myocardial Ischemia/Reperfusion Injury

    by Radhika Rastogi, Katherine Marsh, Aimee Y. Zhang, Di Wu, Mahendra D. Chordia, Dongfeng Pan, Irving L. Kron, Zequan Yang


  • Open Access

    Noninvasive Analysis of Peptidoglycan from Living Animals

    by Karl L. Ocius, Sree H. Kolli, Saadman S. Ahmad, Jules M. Dressler, Mahendra D. Chordia, Brandon L. Jutras, Melanie R. Rutkowski, Marcos M. Pires

    The role of the intestinal microbiota in host health is increasingly revealed in its contributions to disease states. The host-microbiome interaction is multifactorial and dynamic. One of the factors that has recently been strongly associated with host physiological responses is peptidoglycan from bacterial cell walls. Peptidoglycan from gut commensal bacteria activates peptidoglycan sensors in human cells, including the nucleotide-binding oligomerization domain-containing protein 2. When present in the gastrointestinal tract, both the polymeric form (sacculi) and depolymerized fragments can modulate host physiology, including checkpoint anticancer therapy efficacy, body temperature and appetite, and postnatal growth. To utilize this growing area of biology toward therapeutic prescriptions, it will be critical to directly analyze a key feature of the host-microbiome interaction from living hosts in a reproducible and noninvasive way. Here we show that metabolically labeled peptidoglycan/sacculi can be readily isolated from fecal samples collected from both mice and humans. Analysis of fecal samples provided a noninvasive route to probe the gut commensal community including the metabolic synchronicity with the host circadian clock. Together, these results pave the way for noninvasive diagnostic tools to interrogate the causal nature of peptidoglycan in host health and disease.


  • Open Access

    Bioluminescence-Based Determination of Cytosolic Accumulation of Antibiotics in Escherichia coli

    by Rachita Dash, Kadie A. Holsinger, Mahendra D. Chordia, Mohammad Sharifian Gh., Marcos M. Pires

    Antibiotic resistance is an alarming public health concern that affects millions of individuals across the globe each year. A major challenge in the development of effective antibiotics lies in their limited ability to permeate cells, noting that numerous susceptible antibiotic targets reside within the bacterial cytosol. Consequently, improving the cellular permeability is often a key consideration during antibiotic development, underscoring the need for reliable methods to assess the permeability of molecules across cellular membranes. Currently, methods used to measure permeability often fail to discriminate between the arrival within the cytoplasm and the overall association of molecules with the cell. Additionally, these techniques typically possess throughput limitations. In this work, we describe a luciferase-based assay designed for assessing the permeability of molecules in the cytosolic compartment of Gram-negative bacteria. Our findings demonstrate a robust system that can elucidate the kinetics of intracellular antibiotic accumulation in live bacterial cells in real time.


  • Measurement of Accumulation of Antibiotics to Staphylococcus aureus in Phagosomes of Live Macrophages**

    by Joey J. Kelly, Brianna E. Dalesandro, Zichen Liu, Mahendra D. Chordia, George M. Ongwae, Marcos M. Pires

    Staphylococcus aureus (S. aureus) has evolved the ability to persist after uptake into host immune cells. This intracellular niche enables S. aureus to potentially escape host immune responses and survive the lethal actions of antibiotics. While the elevated tolerance of S. aureus to small‐molecule antibiotics is likely to be multifactorial, we pose that there may be contributions related to permeation of antibiotics into phagocytic vacuoles, which would require translocation across two mammalian bilayers. To empirically test this, we adapted our recently developed permeability assay to determine the accumulation of FDA‐approved antibiotics into phagocytic vacuoles of live macrophages. Bioorthogonal reactive handles were metabolically anchored within the surface of S. aureus, and complementary tags were chemically added to antibiotics. Following phagocytosis of tagged S. aureus cells, we were able to specifically analyze the arrival of antibiotics within the phagosomes of infected macrophages. Our findings enabled the determination of permeability differences between extra‐ and intracellular S. aureus, thus providing a roadmap to dissect the contribution of antibiotic permeability to intracellular pathogens.


  • Progressive Cardiac Metabolic Defects Accompany Diastolic and Severe Systolic Dysfunction in Spontaneously Hypertensive Rat Hearts

    by Jie Li, Krzysztof Minczuk, Qiao Huang, Brandon A. Kemp, Nancy L. Howell, Mahendra D. Chordia, R. Jack Roy, James T. Patrie, Zoraiz Qureshi, Christopher M. Kramer, et al.

    Background: Cardiac metabolic abnormalities are present in heart failure. Few studies have followed metabolic changes accompanying diastolic and systolic heart failure in the same model. We examined metabolic changes during the development of diastolic and severe systolic dysfunction in spontaneously hypertensive rats (SHR). Methods and Results: We serially measured myocardial glucose uptake rates with dynamic 2‐[ 18 F] fluoro‐2‐deoxy‐ d ‐glucose positron emission tomography in vivo in 9‐, 12‐, and 18‐month‐old SHR and Wistar Kyoto rats. Cardiac magnetic resonance imaging determined systolic function (ejection fraction) and diastolic function (isovolumetric relaxation time) and left ventricular mass in the same rats. Cardiac metabolomics was performed at 12 and 18 months in separate rats. At 12 months, SHR hearts, compared with Wistar Kyoto hearts, demonstrated increased isovolumetric relaxation time and slightly reduced ejection fraction indicating diastolic and mild systolic dysfunction, respectively, and higher (versus 9‐month‐old SHR decreasing) 2‐[ 18 F] fluoro‐2‐deoxy‐ d ‐glucose uptake rates (Ki). At 18 months, only few SHR hearts maintained similar abnormalities as 12‐month‐old SHR, while most exhibited severe systolic dysfunction, worsening diastolic function, and markedly reduced 2‐[ 18 F] fluoro‐2‐deoxy‐ d ‐glucose uptake rates. Left ventricular mass normalized to body weight was elevated in SHR, more pronounced with severe systolic dysfunction. Cardiac metabolite changes differed between SHR hearts at 12 and 18 months, indicating progressive defects in fatty acid, glucose, branched chain amino acid, and ketone body metabolism. Conclusions: Diastolic and severe systolic dysfunction in SHR are associated with decreasing cardiac glucose uptake, and progressive abnormalities in metabolite profiles. Whether and which metabolic changes trigger progressive heart failure needs to be established.